Several genetic and acquired abnormalities leading to abnormal activation of the alternative pathway of complement have been identified in patients with atypical hemolytic uremic syndrome (aHUS). The purpose of this review is to shed light on how advances in the understanding of aHUS pathogenesis have impacted on prevention and cure of aHUS recurrence after kidney transplantation.
INTRODUCTION
Hemolytic uremic syndrome (HUS) is a rare disorder (incidence, about 2 cases/year/100 000 people) of microangiopathic hemolysis, thrombocytopenia, and renal failure [1] . About 90% of childhood cases are caused by Escherichia coli strains producing Shiga-like toxins (STEC-HUS) and have a good prognosis [2 & ]. Less than 10% of cases are not caused by STEC. This atypical form (aHUS) has a worse outcome with a 10-15% mortality during the first clinical manifestation and up to 50% of cases progressing to end-stage renal disease (ESRD) [1] .
Graft failure for recurrence is reported in 60-80% of patients with aHUS-related ESRD who underwent kidney transplantation [3] . The recurrence risk is major during the first year (accounting for 70% of events). More than 80% of patients who lost the first graft for recurrence also had a recurrence on the subsequent grafts [4 && ]. In a report from 2006, 91.6% of patients with disease recurrence developed graft failure [5] . In the more recent French survey of 57 adult patients receiving 71 grafts, graft survival after recurrence was 44 and 36% at 1 and 5 years, indicating a trend to improvement of prognosis. However, death-censored graft survival was significantly worse in patients with recurrent aHUS than in those without [4 && ].
In the past 15 years, a clear link has been established between aHUS and defects in regulation of the alternative complement pathway ( Fig. 1) [1] ,
GENETIC ABNORMALITIES
Approximately half of aHUS patients have mutations in CFH, CFI, and MCP, encoding the complement regulatory proteins complement factor H, factor I, and membrane-cofactor protein [6] [7] [8] (Fig. 1) . In 3-5% of patients, hybrid genes deriving from uneven cross-over between CFH and CFHR1 have been found [9, 10] . These genetic defects result in gene products with decreased complement regulatory activity on cell surfaces.
Inhibitory anti-CFH antibodies are reported in 5-10% of aHUS patients [11] . They predominantly target the C-terminus of CFH, thereby impairing complement regulation on host cell surfaces. The development of CFH autoantibodies in aHUS has a genetic predisposition, being strongly associated with deletion of CFHR1 gene [12] .
About 3% of patients carry mutations in the gene encoding thrombomodulin (THBD), a membrane-bound anticoagulant protein that modulates complement [13] .
Gain-of-function mutations in key proteins of the alternative pathway, C3, and complement factor B (CFB) have been reported in 10 and 1-2% of patients [14, 15] , respectively ( Fig. 1 ). Mutant proteins are resistant to inactivation by complement regulators [14, 15] .
The above defects lead to unrestricted complement activation, which eventually results in platelet, leukocyte, and endothelial cell activation and microvascular thrombosis.
Incomplete penetrance of aHUS has been reported in mutation carriers, indicating that additional genetic and/or environmental hits are necessary for disease manifestation. In a European survey including 795 patients from four cohorts, 3% of patients carried mutations in two or three complement genes [16 && ]. Within families, the concomitant presence of CFH and MCP risk haplotypes increased aHUS penetrance in combined mutation carriers, further underlying the oligogenic feature of aHUS [16 && ]. Very recently, DGKE mutations were reported in nine kindreds with autosomal recessive inheritance and early aHUS onset [17 && ]. DGKE encodes diacylglycerol kinase-e, which is apparently unrelated to complement. The mechanism by which DGKE mutations cause aHUS remains to be elucidated.
Impact of underlying abnormality on atypical hemolytic uremic syndrome recurrence
The risk of posttransplant aHUS recurrence is dictated by the underlying genetic defect [3, 18] . Table 1 summarizes outcome data from published patients, excluding those who received eculizumab.
In patients with alterations in circulating complement proteins, the risk is very high, as the altered protein is produced by the liver and persists in the circulation after kidney transplantation. Patients with CFH mutations have the highest recurrence rate. Among 60 transplanted patients with CFH genetic abnormalities, aHUS recurrence occurred in 64% of grafts and 82% of recurrences induced graft loss (Table 1) 5, 18] . In the French survey, mutations in CFH were the ones associated with the greatest risk [4 && ]. Notably, all the grafts from patients with the CFH/CFHR1 hybrid gene experienced a recurrence. This very high-risk subset could not be detected by direct sequencing with CFH-specific primers, but required the special technique of multiplex-ligation-dependent probe amplification [9] . This point should be carefully considered during pretransplant screening.
The incidence of recurrence in patients with anti-CFH antibodies is lower than that in patients with CFH mutations (Table 1) [11] . The immunosuppression administered for prevention of allograft rejection might play a role in controlling the antibody titer and preventing disease recurrence. When it occurred, recurrence was severe leading
KEY POINTS
More than 60% of patients with aHUS have genetic abnormalities in complement genes or anti-CFH antibodies. Risk polymorphisms and haplotypes in complement genes determine disease penetrance in mutation carriers.
The risk of aHUS recurrence in the kidney graft strongly depends on the underlying defect.
Kidney liver transplantation surgically corrects the genetic defect in patients with CFH mutations; however, the procedure is associated with 10-20% short-term mortality.
Treatment with the anti-C5 monoclonal antibody eculizumab has been shown to effectively prevent and cure posttransplant aHUS recurrence.
Clinical studies are required to clarify whether and which patients will need life-long eculizumab treatment and to find out suitable tests to monitor optimal complement blockade.
to graft loss in four out of five cases ( Table 1) . Renal transplantation in patients with CFI mutations is also associated with high recurrence rate and poor prognosis ( Table 1) .
Patients with gain-of-function C3 and CFB mutations are at risk as well with 53 and 100% recurrence rates, respectively (Table 1) [3] .
MCP is a membrane-associated complement regulator protein. The recurrence of aHUS in transplanted patients carrying a single MCP mutation is rare, because endothelial cells within the kidney allograft express normal MCP (Table 1 ) [3] . The mechanisms proposed to explain unexpected recurrence in a few patients with MCP mutations include chimerism, as observed in a patient in whom graft endothelial cells were partially replaced by recipient cells expressing mutant MCP [19] . Alternatively, the MCP mutation might be associated with another genetic abnormality. In the large European survey [16 && ], high incidence of recurrence (about 65%) was observed in patients with MCP mutations combined with mutations in other complement genes, contrasting with the good graft outcome among patients carrying an isolated MCP mutation. The concomitant presence of genetic dysfunction in circulating proteins that could not be corrected by a kidney transplant likely contributed to the higher risk of recurrences in the former group. On the same line, in the French cohort, the two patients with isolated MCP mutations who had posttransplant recurrence harbored two at-risk CFH haplotypes [4 && ]. Renal transplantation may be successful in patients with DGKE mutations, encoding an intracellular kinase expressed in podocytes and glomerular endothelial cells. Among three transplanted Factor D (CFD) cleaves factor B to form the AP initiation C3 convertase that cleaves C3 to C3b. The activation is then amplified by the covalent binding of a small amount of C3b to hydroxyl groups on cell-surface carbohydrates and proteins of target cells such as bacterial cells. This C3b binds factor B, to form the amplification loop C3 convertase C3bBb. The binding of properdin (P) stabilizes this enzyme. C3 convertase enzymes cleave many molecules of C3, resulting in a positive feedback amplification loop. C3b also binds to the C3 convertase forming the C5 convertase enzyme C3b 2 Bb. The AP is highly regulated as to prevent nonspecific damage to host cells and limit the deposition of complement to the surface of pathogens. This occurs through a number of membraneanchored and fluid phase regulators. CFH, complement factor H; CFI, complement factor I (degrades C3b); CR1, complement receptor 1 (both act as cofactors for factor I for C3b cleavage and favor the decay of the C3 convertase of the AP); DAF, decay accelerating factor (favors dissociation of the C3 and C5 convertases); MCP, membrane cofactor protein (binds C3b and has cofactor activity).
patients, none experienced posttransplant recurrence [17 && ] ( Table 1) . Complete screening of all disease-associated genes should be performed to allow patients and clinicians make informed decisions regarding listing for transplantation and posttransplant prophylaxis, based on recurrence risk.
SHIGA TOXIN-PRODUCING ESCHERICHIA COLI-HEMOLYTIC UREMIC SYNDROME
At variance with aHUS, STEC-HUS has a low rate of posttransplant recurrence (0-5%) [3] . However, there are rare reports of posttransplant recurrences in patients who developed ESRD following a severe episode of STEC-HUS [3, 18] . A young woman with history of STEC-HUS received a cadaveric kidney transplant that failed 1 year later for recurrence. Genetic screening performed before planning a second transplant revealed a CFI mutation [20 & ]. This case indicates that screening of HUS-associated genes should be performed in patients on dialysis following severe episodes of STEC-HUS, as they may be undiagnosed cases of aHUS precipitated by STEC infection on a genetic background of impaired complement regulation.
PREVENTION OF POSTTRANSPLANT ATYPICAL HEMOLYTIC UREMIC SYNDROME RECURRENCE
Several strategies have been attempted to prevent recurrence of aHUS in the kidney grafts.
IMMUNOSUPPRESSION
An association between the use of calcineurin inhibitors (CNIs) and posttransplant aHUS recurrence was hypothesized [21] . However, more recent studies have found that avoiding CNIs does not help, while exposing patients to risk of acute rejection [4 && ,5]. Of note, the most frequently used CNI-free protocol relied on mammalian target of rapamycin (m-TOR) inhibitors, which are toxic to the endothelium and can induce HUS [22] . In the recent French survey, a CNI-based regimen did not represent a significant risk factor for recurrence [4 && ]. Conversely, m-TOR inhibitors were independently associated with an increased risk [4 && ]. These data suggest that aHUS patients should be treated with CNI with careful monitoring of doses to avoid drug overexposure.
Plasma therapy
Preemptive plasma therapy has been used for prevention of aHUS recurrence [4 
Combined kidney and liver transplantation
Simultaneous kidney and liver transplant was performed in two children with aHUS and CFH mutations based on the rationale that liver replacement provides a source of normal CFH, thus preventing disease recurrence in the transplanted kidney [28, 29] . However, both cases were complicated by premature liver failure with microvascular thrombosis and complement deposition. The first child recovered after a second liver transplantation [28] , whereas the other died few days after transplant because of primary liver nonfunction [29] . The surgical stress with ischemia/reperfusion likely induced complement activation in the liver that could not be regulated because of functional CFH deficiency [30] . A subsequent modified approach [31] included extensive plasma exchange before surgery to provide enough normal CFH until the liver graft recovered synthetic functions. This procedure was successful in eight patients, including one with preserved renal function who received an isolated liver transplant [31-35,36 & ,37] . However, another child with a CFH mutation developed severe hepatic thrombosis and fatal encephalopathy [31] . The risks of kidney and liver transplantation have limited widespread diffusion of this option and require a careful assessment of benefits in candidate patients in view of the available option of isolated kidney transplant under eculizumab prophylaxis.
Eculizumab
Eculizumab is a humanized monoclonal antibody that binds to the human complement C5 and blocks the generation of the membrane attack complex C5b-9 [38] . Several case reports and two phase 2 trials [39, 40 && ] have documented the efficacy and safety of eculizumab in aHUS, which led regulatory agencies in the United States and Europe to approve the drug for aHUS treatment.
The anti-C5 antibody was also efficiently used as prophylaxis to prevent posttransplant aHUS recurrence in 10 patients [41,42 && , [43] [44] [45] [46] [47] in whom a high recurrence risk was predicted from identified genetic abnormalities (Table 2) . Nine patients carried a CFH mutation or a CFH/CFHR1 hybrid gene. The remaining displayed a C3 mutation. Two patients received plasma exchange started just before transplantation and were switched to eculizumab at day 5 and 10 posttransplant, respectively. In three other patients, eculizumab was started 1 week or more before transplant, preceded or not by a plasma exchange. The more common strategy was based on eculizumab alone, started immediately before transplantation ( Table 2 ). Only one patient lost the graft for immediate arterial thrombosis at day 1 posttransplant. The other nine had a successful recurrence-free posttransplant course. Graft function at the last follow-up was good, ranging from 44 to 176 mmol/l. Full blockade of circulating C5 was documented with maintenance dosages of 300-600 mg (pediatric cases) or 900-1200 mg (adult cases) every other week. No patient with preserved graft had discontinued the drug so far [42 && ]. Whether aHUS transplanted patients should continue lifelong eculizumab prophylaxis or whether it can be stopped at any time and used as rescue therapy if clinical signs of relapse occur remain to be established in controlled trials. When compared to kidney-liver transplant, the pros for eculizumab are the lower short-term risk and the effectiveness in preventing recurrences; the cons are the need of chronic treatment, the potential long-term effects of C5-inhibition on the already heavily immunosuppressed transplant recipients, and the high costs. Kidney-liver transplantation is associated with higher short-term complications, but provides surgical correction of the genetic abnormality and could be widely available due to lower monetary cost.
In high-income countries, public health systems and private insurances tend to limit eculizumab use, whereas in low-income and poor countries the high costs prevent its use, and such limitation applies to the large majority of patients worldwide. Thus, efforts to improve kidney-liver transplant procedure are crucially needed, at least till complement inhibitory therapies will become economically affordable.
Rituximab
In patients with anti-CFH antibodies, pretransplant reduction of antibody levels with plasma exchange and antibody-suppressing or depleting agents, such as corticosteroids, azathioprine, mycophenolate mofetil, cyclophosphamide, or the anti-CD20 monoclonal antibody rituximab, is recommended as high anti-CFH antibody levels predispose to recurrence [18] . Pretransplant rituximab administration followed by intensive plasma exchange postoperatively in a 10-year-old girl led to disappearance of antibodies and the patient had no recurrence during 2-year follow-up [48] . In another report of two rituximab-treated patients, one showed normal graft function and negative anti-CFH antibody titer at 4-year follow-up [11] , the other was well at 8-month posttransplant; however, the anti-CFH antibodies did not disappear after rituximab. In one patient with high anti-CFH antibody levels who had lost two previous grafts for recurrence, intensive plasma exchange alone allowed disappearance of antibodies and prevented disease recurrence in the new graft [49] . However, also about half of grafts in patients receiving no specific treatment had a favorable outcome [11, 50] . The immunosuppression administered for preventing rejection might play a role in controlling anti-CFH antibody titer and disease recurrence. In a patient, repeat measurement 6 years following transplantation failed to detect anti-CFH antibodies, suggesting that anti-CFH autoantibodies may be transient in patients on chronic immunosuppression [51] .
A pragmatic approach to the transplant management of patients with anti-CFH antibodies could be to regularly monitor antibody levels and administer rituximab to patients with persistently elevated titers.
TREATMENT OF RECURRENCES
Although plasma exchange is considered effective for de-novo posttransplant aHUS, its effectiveness during recurrence is doubtful [3] . Emerging evidence supports the efficacy of eculizumab to induce remission of aHUS recurrence episodes in the kidney graft.
Plasma exchange
Among 27 published patients who received plasma exchange during aHUS recurrences, only 11 maintained a functioning graft [21, 23, [52] [53] [54] [55] . In the French survey, long-term graft survival following aHUS recurrence was not different among patients treated or not with curative plasma therapy [4 && ]. CNI withdrawal does not appear to give substantial benefit in recurrent aHUS and leaves the patient at risk of acute rejection. A strategy could be to reduce CNI during recurrence and restore the dose after clinical recovery. Plasma exchange combined with belatacept, which blocks the interaction between CD80/86 and CD28, in a patient with recurrent aHUS, allowed CNI discontinuation and reversed disease while preventing acute rejection [56] .
Eculizumab
Eighteen patients have been reported in the literature who received eculizumab to treat posttransplant aHUS recurrence [4 && ,24,42 && ,57-63] ( Table 3 ). All but one were switched from plasma to eculizumab, two were plasma-dependent, whereas 15 had plasma-resistant forms. The remaining received eculizumab as first-line therapy. In all patients, hematological features rapidly normalized following start of eculizumab and renal function also improved in the subsequent months ( Table 3 ). The longer the interval was between aHUS recurrence onset and eculizumab treatment initiation, the lower was the recovery of graft function [42 && ]. These findings are in line with results of the two recently published trials (including 15 patients with posttransplant recurrence), showing continuous time-dependent increases in renal function, with earlier eculizumab intervention associated with greater improvement [40 && ]. These findings, together with evidence that curative plasma therapy failed to improve graft survival [4 && ], indicate the need for a prompt introduction of eculizumab as first-line therapy of posttransplant aHUS recurrences.
Notably, the response to eculizumab was similar among patients in whom a gene mutation was identified and in patients without mutations (Table 3) . Thus, a complete genetic screening is not a prerequisite for decision to start therapy in the presence of clinical signs of relapse.
The high cost of the drug may prompt clinicians to discontinue the drug. However, both a single-dose eculizumab and eculizumab discontinuation after several months were associated with subsequent relapses in four out of four patients, mostly concomitant with infections that triggered complement activation, and resulted in graft loss in three of them despite re-initiation of eculizumab (Table 3 , Fig. 2) . Similarly a few days' delay in anti-C5 infusion in two patients was associated with relapses (Table 3 , Fig. 2 ). Thus, another lesson that could be drawn from previous experience is that eculizumab should not be discontinued or if so it should be done with extreme caution. Of note, active HUS lesions were also observed in two patients receiving eculizumab according to the recommended schedule and with complete blockade of circulating C5 [42 && ] ( Table 3 , Fig. 2 ). However, undetectable C5 activity in plasma does not exclude the presence of residual C5 activation on microvascular endothelial cells. Preliminary ex-vivo data in a transplanted child with signs of aHUS recurrence under eculizumab treatment showed significant C5b-9 endothelial deposition despite nearly complete systemic C5 blockade (Miriam Galbusera, personal communication). This finding indicates the need for tests specifically targeted to endothelial cells to monitor the effectiveness of anti-C5 therapy in aHUS.
CONCLUSION
Evidence of the influence of genotype on risk of posttransplant aHUS recurrence and the effectiveness of eculizumab for treatment of recurrence are clear-cut. However, there are still a number of open issues. The first one is whether all patients should receive posttransplant eculizumab prophylaxis. The answer is probably yes in patients with genetic abnormalities in CFH, CFI, C3, and CFB that are associated with high risk of posttransplant recurrence or in those who experienced a recurrence in a previous graft. In patients with lower risk, such as those with MCP mutations or without identified mutation and no history of recurrences, a stand-by strategy could be adopted with careful monitoring and starting eculizumab immediately at aHUS onset.
The optimal duration of anti-C5 therapy is another open question. It might be individualized based on genetic findings and clinical history. In patients with high-risk mutations or who have experienced a recurrence in a previous graft or have an ongoing recurrence, anti-C5 therapy should not be discontinued unless a combined kidney-liver transplantation is undertaken to definitely cure the disease. In patients with lower risk, attempts to taper off eculizumab after a long recurrence-free period might be a reasonable strategy. However, prospective trials and specific assays of C5 activation on endothelium are critically warranted.
